PRECIS-2 Website references

1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe K, Zwarenstein M:
   The PRECIS-2 tool: Designing trials that are fit for purpose
   BMJ 2015, 350(2147).
2. Forbes G, Loudon K, Treweek S, Taylor S, Eldridge S:
   Understanding the applicability of results from primary care trials: lessons learned from applying PRECIS-2
   Journal of Clinical Epidemiology, 2017
3. Loudon K, Zwarenstein M, Sullivan F, Donnane P, Gágyorf I, Hobbeleng H, Althabeh F, Krishnani J, Treweek S:
   The PRECIS-2 tool has good interrater reliability and modest discriminant validity
   Journal of Clinical Epidemiology, 2017
4. Zwarenstein M, Treweek S, Loudon K:
   Understanding pragmatism and PRECIS-2
   Journal of Clinical Epidemiology, 2017
5. NIH Collaboratory:
   Rethinking Clinical Trials – the living textbook
   www.rethinkingclinicaltrials.org
6. University of Colorado, and the Colorado Research on Implementation Science Program (CRISP)
   E-book on pragmatic trials, with an emphasis on using the PRECIS-2 framework and incorporating stakeholder engagement
   www.CRISPeBooks.org
7. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K:
   A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers
   Journal of Clinical Epidemiology 2009, 62(5):464-75.
8. Loudon K, Zwarenstein M, Sullivan F, Donnan P, Treweek S:
   Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose
   Trials 2013, 14:115.
9. Rothwell PM:
   Treating Individuals 1 - External validity of randomised controlled trials: "To whom do the results of this trial apply?"
   Lancet 2005, 365:82-93.
10. Treweek S, Zwarenstein M:
    Making trials matter: pragmatic and explanatory trials and the problem of applicability
    Trials 2009, 10.
11. Karanicolas PJ, Montori VM, Devereaux PJ, Schünemann H, Guyatt GH:
    A new 'mechanistic-practical" framework for designing and interpreting randomized trials
    Journal Of Clinical Epidemiology 2009, 62:479-484.
12. Oxman AD, Lombard C, Treweek S, Gagnier JJ, Maclure M, Zwarenstein M:
    Why we will remain pragmatists: four problems with the impractical mechanistic framework and a better solution
    Journal of Clinical Epidemiology 2009, 62: 485-488
13. Karanicolas PJ, Montori VM, Devereaux PJ, Schünemann H, Guyatt GH:
    The practicalists' response
    Journal Of Clinical Epidemiology 2009, 62:489-494.
14. Oxman AD, Lombard C, Treweek S, Gagnier JJ, Maclure M, Zwarenstein M:
    A pragmatic resolution
    Journal of Clinical Epidemiology 2009, 62:495-498.
15. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, Grp C, Pragmatic Trials Healthcare P:
    Improving the reporting of pragmatic trials: an extension of the CONSORT statement
    British Medical Journal 2008, 337.
16. Zwarenstein M, Treweek S:
    What kind of randomized trials do we need?
    Canadian Medical Association Journal 2009, 180:998-1000.
17. Higgins, J. P. and Altman, D. G. (2008)
    Assessing Risk of Bias in Included Studies
    Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series (eds J. P. Higgins and S. Green), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470712184.ch8
18. Higgins J, Altman D, Gøtzsche P, Jüni P, Moher D, Oxman A, Savović J, Schulz K, Weeks L, Sterne J:
    The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
    BMJ 2011, 343.